Sisunatovir (Synonyms: RV521) |
カタログ番号GC62216 |
RSV 融合 (RSV-F) タンパク質の経口投与可能な阻害剤であるシスナトビル (RV521) は、RSV-A および RSV-B ウイルスの臨床分離株のパネルに対して、それぞれ 1.4 nM および 1.0 nM の IC50 で強力な有効性を示します[ 1]。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1903763-82-5
Sample solution is provided at 25 µL, 10mM.
Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively[1].
[1]. DeVincenzo J, et al. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrob Agents Chemother. 2020;64(2):e01884-19. Published 2020 Jan 27.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *